KRAS and colorectal cancer: Examining primary tumor samples from 113 patients with colorectal cancer, Watanabe et al. [160] later observed that KRAS mutant tumors (31 %) exhibited a distinct gene expression signature compared with their WT counterparts (69 %) where Spry2 was among the 30 genes upregulated in the KRAS mutants.